On May 17, the AANS and the CNS joined the Alliance of Specialty Medicine in sending a letter addressing issues raised in a Federal Trade Commission (FTC) Request for Information related to the pharmacy benefit manager (PBM) industry. PBMs are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers and other payers. The letter expressed concern about the consolidation in the PBM industry, noting that just three PBMs control 80% of prescriptions in the U.S. It urged the FTC to thoroughly study PBM industry practices and their impact on the availability and cost of prescription medication for patients.
Click here to read the Alliance of Specialty Medicine’s letter.
